




**Supplementary materials:**




**Figure S1.** The morphology alternation of *TVF*-treated A549 cells.



**Figure S2.** The cell viabilities of A549 cells treated with 3-caffeoylquinic acid (3-CA), 5-caffeoylquinic acid (5-CA), quercetin-3-O-rutinoside (Q3R), and kaempferol-3-O-rutinoside (K3R).



**Figure S3.** The cell viabilities of *TVF*-treated A549 cells treated with or without 3-MA.



**Figure S4.** The cellular morphologies of *TVF*-treated A549 cells treated with or without 3-MA.